Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 4Thoracic 3Breast 3Gynecologic 2Other solid neoplasm 1Lymphoid 1CNS 1

Conditions

Neoplasms 3Neoplasm Metastasis 1

Interventions

pembrolizumab 95Paclitaxel 86Gemcitabine 84Carboplatin 79Surveys and Questionnaires 72Docetaxel 61Bevacizumab 61Nivolumab 59Cisplatin 59Magnetic Resonance Spectroscopy 50Blood Specimen Collection 50Fluorouracil 48Radiotherapy 47Capecitabine 47Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 38Biopsy 36atezolizumab 35Leucovorin 35Pemetrexed 34Standard of Care 32Cetuximab 32Specimen Handling 31Trastuzumab 30Radiosurgery 29Ipilimumab 28Cyclophosphamide 28Interviews as Topic 27olaparib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
XL147 × Tumor-Agnostic × Clear all
NCT01587040 2022-04-19

Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen

Sanofi

Phase 1/2 Completed
61 enrolled 13 charts
Tumor-Agnostic

Neoplasms

NCT01943838 2016-04-22

A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma

Sanofi

Phase 1 Completed
18 enrolled
Tumor-Agnostic

Neoplasms

NCT01357330 2016-04-01

Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors

Sanofi

Phase 1 Completed
18 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT01392924 2014-12-03

Safety and Pharmacokinetics of SAR245408 Daily Oral in Patients With Solid Tumors

Sanofi

Phase 1 Completed
10 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡